SOUTH SAN FRANCISCO, Calif., Nov. 1, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in investor conferences in November 2021.
Northland Capital Biotech Best Ideas Event
Wednesday, November 17, 2021
- CEO Roundtable with IDEAYA participation by Yujiro Hata, Chief Executive Officer, hosted by Tim Chiang, Managing Director, Senior Analyst at 9:30am ET
- Panel Discussion "New Advances in Synthetic Lethality", with IDEAYA participation by Michael White Ph.D., Chief Scientific Officer, participating at 10:45am ET
- Company Presentation by Yujiro Hata, Chief Executive Officer, at 1:00pm ET
Jefferies London Healthcare Conference
Thursday, November 18, 2021
- Fireside chat with Yujiro Hata, Chief Executive Officer, hosted by Maury Raycroft Ph.D., Equity Research Analyst, at 6:00pm GMT
A live audio webcast of each event will be available, as permitted by conference host, at the "Investors/News and Events/Investor Calendar" section of the IDEAYA website at https://ir.ideayabio.com/events. A replay of available webcasts will be accessible for 30 days following the live event.
About IDEAYA Biosciences
IDEAYA is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's Quarterly Report on Form 10-Q filed on August 10, 2021 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.
SOURCE IDEAYA Biosciences, Inc.